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The combination of chemotherapy and immune check-
point inhibition (ICI) therapy is the current standard of
care for most patients who are fit to undergo treatment
for metastatic NSCLC. With this combination, renal
toxicity was slightly higher than with chemotherapy
alone in initial clinical trials. However, in recent real-
world data, loss of kidney function is reported to be
more frequent. Both chemotherapy and ICI therapy can
induce renal impairment, although the mechanism of
renal damage is different. Renal injury from chemo-
therapy is often ascribed to acute tubular injury and
necrosis, whereas the main mechanism of injury caused
by ICI therapy is acute tubulointerstitial nephritis. In
cases of concomitant use of chemotherapy and ICI
therapy, distinguishing the cause of renal failure is a
challenge. Discriminating between these two causes is of
utmost importance, as it would help assess which drug
can be safely continued and which drug must be halted.
This review aims to describe the underlying mecha-
nisms of the renal adverse effects caused by chemo-
therapy and ICI therapy, leading to a suggested
diagnostic and treatment algorithm on the basis of
clinical, laboratory, radiographic, and pathologic param-
eters. This algorithm could serve as a supportive tool
for clinicians to diagnose the underlying cause of acute
kidney injury in patients treated with the combination
of chemotherapy and immunotherapy.
Keywords: Renal toxicity; Immunotherapy; Checkpoint in-
hibitor; Pemetrexed; NSCLCJournal of Thoracic Oncology Vol. 15 No. 9: 1472–83Introduction
For many years, the first-line treatment for advanced
NSCLC was a combination of platinum-based chemo-
therapy. On the basis of the Keynote-024 study results,
in patients with stage IV NSCLC without EGFR mutation
or ALK translocation and programmed death-ligand 1
(PD-L1) expression of greater than or equal to 50%,
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because of a significantly longer progression-free and
overall survival than with chemotherapy (both
p < 0.001).1 Recently, the phase 3 Keynote-189 trial
reported that in previously untreated patients with
advanced nonsquamous NSCLC without EGFR mutation
or ALK translocation, the progression-free and overall
survival were significantly longer with the addition of
pembrolizumab to platinum-pemetrexed chemotherapy
than with chemotherapy alone, irrespective of PD-L1
expression of the tumor (both p < 0.001).2 This combi-
nation therapy is now considered a standard of care for
most patients who are fit to undergo treatment for
advanced nonsquamous NSCLC.
One of the major concerns about combination treat-
ment with different antitumor drugs is toxicity, as this
may have a major impact on the quality of life and may
lead to the withdrawal of effective treatment in patients.
Although the overall reported frequency is still low,
renal toxicity seems to be more frequent in the setting of
the chemotherapeutic agent pemetrexed in combination
with the immune checkpoint inhibitor (ICI) pem-
brolizumab. According to Common Terminology Criteria
for Adverse Events version 4.0 (CTCAE version 4.0), in
the Keynote-24 trial comparing pembrolizumab with
standard chemotherapy in the first-line setting, nephritis
grades 3 to 5 were seen in 0.6% of the patients receiving
immunotherapy.1 In addition, increased creatinine was
reported in 1.9% of these patients. In the Keynote-189
study, acute kidney injury (AKI), as defined by CTCAE
version 4.0, was observed in 5.2% of the patients in the
pembrolizumab-combination group compared with only
0.5% in the placebo-combination group. A total of 12.2%
of the patients treated with pembrolizumab and
carboplatin-pemetrexed revealed all-grade increased
blood creatinine, of which 0.7% were grades 3 to 4.
Renal adverse events in the pembrolizumab-combination
group led to treatment discontinuation in 2% of the
patients. Most patients in this trial received chemo-
therapy with carboplatin as the platinum compound, and
only about 25% received the more nephrotoxic cisplatin.
Although initial clinical trials reported a low incidence of
immunotherapy-related nephrotoxicity, emerging data
suggest a higher incidence rate between 13.9% and 29%,
especially when chemotherapy and immunotherapy are
combined.3
Discrepancies between results of clinical trials and
real-world data are also present with regard to
pemetrexed-induced nephrotoxicity. In the pivotal
PARAMOUNT trial (A Phase 3, Double-Blind, Placebo-
Controlled Study of Maintenance Pemetrexed plus Best
Supportive Care versus Best Supportive Care Immedi-
ately Following Induction Treatment with Pemetrexedþ Cisplatin for Advanced Non-Squamous Non-Small
Cell Lung Cancer), only less than 10% of the patients
treated with pemetrexed maintenance therapy experi-
enced renal impairment and less than 5% had to dis-
continue treatment owing to nephrotoxicity.4 Several
retrospective studies had already described a higher
incidence (17%–21%) of renal impairment with
pemetrexed.5,6 In this prospective cohort study by our
group, frequencies of approximately 30% for acute
kidney disease (AKD) and up to 20% for treatment
discontinuation were reported during pemetrexed
maintenance treatment.7
As platinum, pemetrexed, and pembrolizumab are
now often combined, it becomes a challenge to distinguish
between chemotherapy- and pembrolizumab-induced
renal adverse events. However, discriminating between
these causes is of utmost importance as misdiagnosis of
the causative agent may lead to inappropriate in-
terventions, which potentially may cause further deteri-
oration of renal toxicity, interruption or even cessation of
an effective treatment. This review aims to describe the
mechanisms of the renal side effects caused by the
frequently used combination of platinum, pemetrexed,
and pembrolizumab, leading to a suggested diagnostic
and treatment algorithm. Other oncological therapeutic
agents will not be covered in this article.
Definition of Renal Toxicity
Estimations of the frequency of kidney injuries in
clinical studies depend on how kidney injury has been
defined. In the field of oncology, (renal) adverse events
are reported according to the descriptive terminol-
ogies of CTCAE providing a grading (severity) scale for
each adverse event (Table 1).8 In CTCAE version 4.0,
an important adjustment has been made that takes
into account the absolute increase of creatinine and its
relative increase from baseline. Notably, in the newest
version (version 5.0), the lower grades (1/2) of AKI
are not anymore defined and severe AKI (grade >3) is
only based on the need for hospitalization or dialysis
and not on measured kidney function. The Acute Kid-
ney Injury Working Group of Kidney Disease:
Improving Global Outcomes (KDIGO) proposed the
most frequently used definitions of kidney disease
nowadays and they divided renal injury into three
categories on the basis of the duration of renal func-
tion deterioration: AKI, AKD, and chronic kidney dis-
ease (CKD) (Table 1).9 All individuals, including the
elderly, with a glomerular filtration rate (GFR) less
than 60 mL/min are considered to have CKD.9
Although some decline of GFR is expected with age,
most healthy older individuals do not necessarily have
a decreased GFR.9 Moreover, among older individuals,
Table 1. Definitions and Classifications of Kidney Injury According to CTCAE and KDIGO
CTCAE
Version 3.0 Grade 1 Grade 2 Grade 3 Grade 4
Creatinine >ULN–1.5  ULN >1.5–3.0  ULN >3.0–6.0  ULN >6.0  ULN
GFR <75%–50% LLN <50%–25% LLN <25% LLN, chronic
dialysis not
indicated
Chronic dialysis or renal
transplant indicated
Version 4.03
AKI Creatinine level
increase of >0.3
mg/dL (26.5 mmol/
liter); creatinine
1.5–2.0  above
baseline
Creatinine 2–3 
above baseline
Creatinine >3 
baseline or >4.0
mg/dL (354
mmol/liter);
hospitalization
indicated
Life-threatening
consequences; dialysis
indicated
Version 5.0
AKIa — — Hospitalization
indicated
Life-threatening
consequences; dialysis
indicated
KDIGO
AKI Increase in serum creatinine by 50% within 7 d or Increase in serum creatinine by 0.3 mg/dL (26.5 mmol/liter) within 2
d or Oliguriab
Stage 1 Stage 2 Stage 3
Creatinine: 1.5–1.9  baseline
or  0.3 mg/dL (26.5 mmol/
liter)
Creatinine: 2.0–3.0 
baseline
Creatinine: >3.0  baseline or  4.0
mg/dL (354 mmol/liter)
AKD AKI or GFR < 60 mL/min per 1.73 m2 for <3 mo or decrease in eGFR by >35% or increase in serum creatinine>50% for
<3 mo
CKD GFR <60 mL/min per 1.73 m2 for >3 mo
G1 (normal) G2c G3A G3B G4 G5 (renal failure)
GFR 90 GFR 60–89 GFR 45–59 GFR 30–44 GFR 15–29 GFR <15
aA disorder characterized by the acute loss of renal function (within 2 weeks).
bOliguria is also used in the staging of AKI, but it is not further discussed here.
cGFR 60–89 mL/min is considered to be mildly decreased, but the threshold of GFR <60 mL/min (G3a–G5) is chosen for CKD.
AKD, acute kidney disease; AKI, acute kidney injury; CKD, chronic kidney disease; CTCAE, Common Terminology Criteria for Adverse Events; eGFR, estimated
glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes; LLN, lower limit of normal; ULN, upper limit of normal.
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mortality and kidney failure.10 In an earlier study by
our group, renal adverse events were graded according
to CTCAE 4.03 and CTCAE 3.0 to allow for comparison
of data from the registration trial of pemetrexed
maintenance treatment.7 Among patients who devel-
oped AKD during maintenance pemetrexed therapy
per KDIGO definitions, 77% had all grades of renal
adverse events using CTCAE 4.03 but only 54% using
CTCAE 3.0. Hence, using CTCAE 3.0, we found that
only 16% of the patients experienced renal adverse
events in contrast with 30% when using the KDIGO
definitions. This study illustrates the probable under-
estimation of renal toxicity by using CTCAE 3.0 and
4.03 than AKD (KDIGO). By taking into account abso-
lute increases of creatinine and its relative increase
from baseline, the results of the updated version
CTCAE 4.03 corresponded better with the AKD results.Mechanisms of Renal Toxicity
Antitumor drugs can cause renal toxicity by different
mechanisms. Renal injury owing to chemotherapy isoften ascribed to acute tubular injury and necrosis
(ATN) whereas the main mechanism of injury owing to
immunotherapy is acute tubulointerstitial nephritis
(ATIN).11,12 AKI is associated with immediate- and long-
term unfavorable outcomes and the development of
CKD.13 Therefore, it is of utmost importance to rapidly
identify the cause and start the appropriate manage-
ment. Uncovering the underlying mechanisms can be the
key to the management of AKI during the combination
treatment of chemotherapy and immunotherapy. In the
case of ATIN, timely administration of steroids can
salvage kidney tissues by reducing the amount of tubu-
lointerstitial fibrosis that may ultimately develop.14
Below we discuss several separate chemotherapeutic
agents used in the treatment of NSCLC in the Keynote-
189 trial, followed by ICI.Cisplatin
Cisplatin is a platinum compound that is widely used
as a cornerstone of chemotherapeutic therapy for many
carcinomas, sarcomas, and lymphomas. One of its major
adverse events is nephrotoxicity, which is often (partially)
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Figure 1. Mechanisms underlying chemotherapy- and immune checkpoint–induced kidney injury. After the entrance of
tubular cells, polyglutamation leads to entrapment of pemetrexed in the cell, as these polyglutamates are not substrates for
ABC transporters. Impaired RNA and DNA synthesis lead to acute tubular injury. Cisplatin induces multiple intracellular injury
pathways, including inflammation, oxidative stress, apoptotic pathways, and DNA damage mediating renal tubular cell injury.
Immune activation by checkpoint inhibitors leads to the development of autoimmunity, reactivation of memory T cells
previously primed by exogenous drug exposure, and an increase in proinflammatory cytokines/chemokines in kidney tissue.
ABC, adenosine triphosphate–binding cassette transporter; Cis, cisplatin; FR-a, folate receptor alpha; OAT1, organic anion
transporter 1; OCT2, organic cation transporter 2; PD-L1, programmed death-ligand 1; Pmx, pemetrexed; Pmx-glut;
pemetrexed polyglutamates; RFC, reduced folate carrier.
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pally excreted by the kidneys and thus, its concentrations
in the renal cortex are high compared with plasma and
other organs.
A key role in the development of cisplatin-mediated
nephrotoxicity might be ascribed to basolateral drug
transporters, as the expression of proximal tubule
organic cation transporter 2 (OCT2) has been reported
to influence intracellular accumulation.16 After cisplatin
enters the tubular cell, multiple intracellular injury
pathways, including inflammation, oxidative stress,
apoptotic pathways, cytoplasmic organelle dysfunction,
and DNA damage can contribute to kidney injury.17 The
renal tubular cell injury ultimately leads to clinical AKI
by ATN and apoptosis (Fig. 1). Another usually observed
manifestation of nephrotoxicity is hypomagnesemia by
decreased renal tubular reabsorption, which occurs in
40% to 100% of patients.18 Less common manifesta-
tions of nephrotoxicity are thrombotic microangiopathy
(TMA), Fanconi-like syndrome, distal tubular acidosis,
and renal concentrating defect.17 Despite renoprotective
strategies including hydration and diuresis, magnesiumsupplementation, and mannitol, approximately one-
third of patients treated with cisplatin still develop
renal impairment after the initial dose. Cisplatin-
induced nephrotoxicity is dose-dependent and also in-
creases with recurrent drug administration.19 In pa-
tients with thoracic malignancies (mostly NSCLC),
cisplatin-induced AKI was observed in 21% of the pa-
tients.15 In this study by our group, the frequency of AKD
accumulated from 20% during cycle 1 to 50% during
cycle 4 in patients treated with combined cisplatin-
pemetrexed treatment.7Carboplatin
Carboplatin has a lesser nephrotoxic profile than
cisplatin, despite the fact that the elimination of carbo-
platin is primarily renal through glomerular filtration. Its
lower nephrotoxic potential can most likely be explained
by a lack of cell transport by OCT2, thereby reducing
proximal tubular intracellular accumulation. In addition,
the chloride at cis-position in cisplatin is replaced by
carboxylate in carboplatin, which is thought to further
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incidence of renal toxicity of carboplatin is the fact that
dosing is based on the renal clearance of the patient.
Thus, in the case of a declining kidney function, the dose
of carboplatin will be adapted, which is not the case with
patients treated with cisplatin. Nevertheless, renal
adverse events are observed during carboplatin-based
chemotherapy with direct tubular injury as the most
common primary mechanism, followed by magnesium-
wasting. A meta-analysis on the basis of individual pa-
tient data from phase II and III trials revealed a signifi-
cantly higher incidence of grade 3 to 4 nephrotoxicity in
patients treated with various combinations of chemo-
therapy combined with cisplatin compared with carbo-
platin (1.5% versus 0.5%, p ¼ 0.018).20 In a real-life
setting, approximately 20% of the patients having
carboplatin-pemetrexed treatment developed AKD.7
Pemetrexed
Pemetrexed is an antifolate agent that inhibits mul-
tiple enzymes involved in the synthesis of purine and
thymidine nucleotides. After cell entrance, pemetrexed
undergoes rapid intracellular polyglutamation, resulting
in polyglutamates that are more potent inhibitors of the
enzymatic processes involved in de novo DNA synthesis.
Pemetrexed does not undergo substantial metabolization
and the unchanged parent compound is primarily elim-
inated through the kidneys with 70% to 90% of the
administered drug excreted unchanged into urine within
24 hours.21 Although pemetrexed is often combined with
cisplatin or carboplatin, pemetrexed monotherapy can
also cause renal failure. Although the pathologic mech-
anism of pemetrexed-induced renal injury is not fully
understood, histopathology in several case reports
described distinct patterns of tubular toxicity.11 Reduced
folate carrier is the main entrance transporter of
pemetrexed and is expressed on basolateral membranes
of kidney tubules, whereas the folate receptor-alfa pro-
vides drug uptake at the apical site.11 Pemetrexed pol-
yglutamation results in prolonged retention of
polyglutamates intracellularly, which in turn may lead to
further impairment in RNA and DNA synthesis and, ul-
timately, tubular injury (Fig. 1). The cumulative systemic
dose of pemetrexed might play a role in the development
of nephrotoxicity.22 Permanent impairment of the kidney
function after discontinuation of the pemetrexed main-
tenance therapy has been reported.23
Immune Checkpoint Inhibitors
ICIs are monoclonal antibodies targeted at a specific
receptor, either programmed cell death protein-1 (PD-1)
or PD-L1, to counteract the blockade of cytotoxic T cells
by PD-L1–up-regulating tumor cells. Using thismechanism, the inhibition of T cells is released and the
immune system can then effectively kill the cancer cells.
However, PD-L1 is also constitutively expressed in renal
cells and is up-regulated by IFN-g.24 By administrating
an anti–PD-1 or anti–PD-L1 antibody, the PD-1 receptor
will be blocked causing proliferation of T cells and
cytotoxic injury of the kidney. It has been speculated that
PD-L1 inhibitors potentially lead to less autoimmune
toxicity owing to diminished blockade of the negative
inhibitory signal, caused by the persistent interaction
between PD-1 and its other ligand PD-L2. A systematic
review revealed a similar incidence of adverse events in
patients treated with PD-1 and PD-L1 inhibitors.25
Although renal toxicity was not described separately,
there was a trend toward a higher incidence of the
overall rate of immune-related adverse events (irAEs)
with PD-1 inhibitors but the number of grades greater
than or equal to 3 irAEs was comparable.
Thus, kidney injury might be caused by the loss of
peripheral tolerance of self-reactive T cells against
endogenous kidney antigens, leading to an autoimmune
variant of interstitial nephritis.26 Alternatively, ICI may
induce reactivation of drug-specific T cells primed by
nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory
drugs [NSAIDs]).12 As associations between drug-
specific T cells and ATIN have been described, it is
plausible that ICI may reactivate these latent drug-
specific T cells.27 Another hypothesis-driven explana-
tion is that the increase of proinflammatory cytokines or
chemokines may mediate inflammatory injury in the
kidney tissue.28 In contrast with the pharmacokinetics of
previously mentioned chemotherapeutic agents, ICIs are
not eliminated by the kidneys but cleared primarily by
proteolytic degradation in plasma and peripheral
tissues.29
Renal parenchymal damage because of ICI can be
subdivided into two types: ATIN and more rarely,
glomerular diseases.3 In addition, one case report
described TMA as a result of checkpoint inhibition.30
However, TMA is also associated with malignancies in
general, which makes it uncertain if TMA can be caused
by checkpoint inhibition.31 TMA is characterized by he-
molytic anemia owing to red blood cell fragmentation,
thrombocytopenia owing to platelet consumption, and
end-organ damage owing to microvascular thrombi.32
Drug-induced TMA has also been reported after treat-
ment with a number of chemotherapeutic agents,
including gemcitabine and the already mentioned
cisplatin.33 The exact incidence of drug-induced TMA is
difficult to estimate because cases are underreported
and the clinical presentation is sometimes confused with
other causes. The mechanism by which the chemother-
apeutic agent induces TMA can either be non–dose-
September 2020 Renal Toxicity of Pemetrexed and Pembrolizumab 1477dependent (immune-related) or more frequently
dose-related (toxic).34 In a patient with severe acute
renal failure after treatment with the nivolumab and
ipilimumab combination therapy, a combination of acute
interstitial nephritis and TMA-like lesions were found in
the renal biopsy.35
ATIN induced by ICI is caused by the migration of T
cells into the kidneys resulting in severe inflammatory
cell infiltrates with or without granuloma. This mecha-
nism can occur as early as days after treatment initiation
but a considerable delay in the development of AIN is
often observed with a median time of 3 months and even
as late as 12 months in some cases.12,36 Immune-
mediated kidney involvement is relatively rare
compared with other organs such as the skin, gastroin-
testinal tract, endocrine glands, and liver; however,
when ICI causes nephrotoxicity, it can be severe and
treatment must be initiated quickly. Timely administra-
tion of steroids can salvage kidney tissues by reducing
the amount of tubulointerstitial fibrosis that may ulti-
mately develop.14Evaluation and Management of Acute
Kidney Injury
As described above, renal impairment during treat-
ment with chemotherapy and ICI is common but their
pathophysiologic mechanisms are different. The pres-
ence of CKD (estimated GFR [eGFR] <60 mL/min) before
treatment is a known risk factor for AKI. Baseline renal
function should be measured before the start of
platinum-pemetrexed treatment and immunotherapy as
even mildly decreased renal function (eGFR 60–90 mL/
min) can predispose the kidneys to chemotherapy-
induced nephrotoxicity.7,37 In addition to baseline
values of creatinine and eGFR, monitoring these pa-
rameters during treatment before each (next) adminis-
tration is needed. Some important pitfalls with regard to
measuring renal function must be addressed. First, eGFR
is only reliable when plasma creatinine is in steady state,
which is not the case in AKI. Therefore, KDIGO states that
only an absolute or relative change of creatinine within
48 hours and 7 days, respectively (or loss of urine
output), can be used for the diagnosis of AKI (Table 1).
The AKD definition takes into account changes in both
creatinine and eGFR. In clinical practice, using the AKD
definition is more convenient, as it allows for compari-
son between these values with a time interval up until 3
months. Second, eGFR is dependent on creatinine values.
In patients with advanced age, muscle wasting, and poor
nutritional status, the use of eGFR may lead to an over-
estimation of actual renal function.
Before starting chemotherapy in combination with
ICI, withdrawal of potential nephrotoxic comedicationshould be considered. The use of high-dose NSAIDs is
(relatively) contraindicated in the days before and after
pemetrexed administration and contraindicated in pa-
tients with impaired renal function at baseline (Food and
Drug Administration–labeled pemetrexed). Besides
NSAIDs, interruption of the use of diuretics, angiotensin-
converting enzyme inhibitors, or angiotensin II receptor
blockers should be considered, as different studies have
revealed an association between nephrotoxicity and the
use of these agents during platinum chemotherapy.38,39
Among patients treated with ICI, 60% were taking
drugs known to potentially cause ATIN40; thus, discon-
tinuation of these drugs should be considered.
A diagnostic algorithm for AKI during the treatment
of chemotherapy in combination with immunotherapy
has been developed on the basis of clinical, laboratory,
radiographic, and pathologic parameters (Fig. 2).Clinical Evaluation
When AKI is observed during treatment, it is impor-
tant to critically evaluate again whether all potential
nephrotoxic medication has been withdrawn, if possible.
Another mechanism that may contribute to renal failure
in patients treated with systemic therapy for lung cancer
is intravenous contrast administration during imaging
procedures. These agents cause contrast-induced acute
kidney injury by direct and indirect nephrotoxic ef-
fects.41 Patients treated with chemotherapy and immu-
notherapy are frequently exposed to contrast agents
because they undergo follow-up computed tomography
(CT) scans regularly to evaluate response to the treat-
ment. The KDIGO working group defined contrast-
induced AKI (definition in Table 1) as AKI after expo-
sure to a contrast medium. Preexisting CKD is the
strongest independent risk factor for contrast-induced
acute kidney injury.41 For this reason, the use of intra-
venous contrast must be carefully considered in each
patient, especially in patients with preexisting kidney
disease. Although increments of plasma creatinine levels
meeting the AKI criteria are not uncommon, the inci-
dence of severe AKI owing to contrast-enhanced CT is
low with a rate of 0.3% postprocedure dialysis.42
Therefore, in the context of the frequently detected
decreasing renal function in patients undergoing sys-
temic treatment for lung cancer, the risk of using intra-
venous contrast should be carefully weighed against the
benefit and should not be a routine procedure when a CT
scan is ordered.
Symptoms may be observed with ATIN, such as
generalized malaise, fatigue, weakness, fever, and
anorexia. It is impossible to distinguish the cause of these
nonspecific symptoms in the presence of malignant dis-
ease. Interestingly, in 60% of patients in this case series
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AKI, at least one extrarenal irAE was documented before
or concurrently with AKI onset.37 In addition, the time of
onset of AKI seems to be delayedwith amedian of 91 days
(interquartile range 60–183 d) and patients could still
develop ATIN 2 months after treatment discontinua-
tion.12 Thus, concomitant extrarenal irAEs at the time of
AKI may raise the suspicion of immunotherapy-related
renal toxicity. The timing of AKI is unlikely to help
distinguish between immunotherapy- or chemotherapy-
related renal toxicity during combination treatment,
except for patients who have a very rapid onset of renal
impairment after initiation of the treatment, which is
suggestive of chemotherapy-related toxicity.
Blood Testing
None of the blood tests is helpful in pointing the
differential diagnosis of AKI toward ATIN. Serum
eosinophils may be moderately or highly elevated (up toDisconnue nephrotoxic med
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Blood tests in combination with urine chemistry
studies may be helpful in distinguishing prerenal versus
renal injury from ATN. Fractional excretion of sodium
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measures of tubular resorption of sodium and urea,
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Pre-renal disease
 
Probable ATIN
(due to ICI)
y 
teinuria AND/OR
aturia AND/OR
rile pyuria
Start steroids
No improvement?
yes
yes
no
yes
Connue monitoring:
Progression?
AKI Stage 1?
Fluid suppleon
no
yes
d ICI
during combination chemotherapy/immunotherapy. *AKI is
reases in eGFR and a longer time interval (<3 mo) for renal
taken into account. AKI, acute kidney injury; ATIN, acute
FR, estimated glomerular filtration rate; FeNa, fractional
O, Kidney Disease Improving Global Outcomes; ICI, immune
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the kidney function before treatment, as a decreased
creatinine clearance (CrCl) at baseline may be predictive of
sensitivity to kidney dysfunction during treatment. In our
previous study, we also established that a decline in renal
function during treatment is predictive for developing
renal failure.7 In addition, the trend of renal function dur-
ing treatment should be noted. Although values may still be
within a normal range, a decreasing renal function during
induction treatment may predict the occurrence of AKI
during maintenance treatment.7
Urinalysis
Urinalysis is a simple test but is the most important
noninvasive test in the general workup of AKI (Table 2).
In ATIN, sterile pyuria is present in most cases, and
microscopic hematuria without casts can be seen, sug-
gesting nonglomerular disease. Proteinuria is mild,
generally revealing protein concentrations less than 2 g/
d. White blood cell casts may be observed, although
sensitivity is low.47 In contrast, ATN is characterized by
the presence of (deeply-pigmented) granular and/or
renal tubular epithelial cell casts with or without free
renal tubular epithelial cells.48
PD-1–related ATIN seems to present similarly to
other causes of ATIN, with evidence of pyuria and
subnephrotic-range proteinuria in 60% and 50% of
the patients, respectively.12 Red blood cells were also
detected in approximately 60% of the patients. Urinary
cytokine IL-9 and tumor necrosis factor-a effectively
distinguished ATIN from other renal lesions in patients
treated with ICI, but these biomarkers still need
validation.49Imaging
If prerenal disease is excluded or severe AKI is
present, an ultrasound should be performed to rule out
postrenal disease caused by urinary tract obstruction.
A CT may be performed when hydronephrosis or uri-
nary tract obstruction cannot be reliably excluded by
ultrasound. Kidney imaging with gallium-67 scintig-
raphy has been proposed in the evaluation of ATIN, as
positive enhancement is seen if the administered
gallium-67 binds to lactoferrin, which is released by
leukocytes within the kidney interstitium. However,
sensitivity (58%–100%) revealed a large variation and
specificity (50%–60%) is low.50 The role of imaging
during the workup of AKI in chemotherapy and
immunotherapy combination is limited to excluding
postrenal disease. However, when imaging procedures
are requested, the use of intravenous contrast must be
carefully considered to prevent further decrease in
kidney function.Renal Biopsy
The regular procedure for the distinction between
chemotherapy- or immunotherapy-induced renal toxicity
is a renal biopsy. Renal toxicity caused by chemotherapy
reveals ATN, whereas renal toxicity as a consequence of
immunotherapy reveals ATIN (Fig. 3). ATIN is charac-
terized by marked mononuclear cell infiltration and a
variable number of lymphoid follicles and tubulitis.
There is a strong infiltration of mainly CD3þ T cells, many
of which are CD4þ T helper cells with a mild infiltrate
of CD8þ cytotoxic T cells and CD20þ B-lymphocytes
(Fig. 3B–D).12 CD68þ and CD163þ macrophages are
also seen, together with CD1cþ dendritic cells. The more
uncommon mechanisms of immunotherapy-induced
renal disease have previously been published as case re-
ports and these include TMA, minimal change disease,
immune complex glomerulonephritis, and drug-induced
lupus nephritis.51-53 Although TMA can be diagnosed
histomorphologically, minimal change disease can only be
diagnosed with confidence using electron microscopy
and the latter two require confirmation through the
exhibition of the characteristic immunofluorescence
staining pattern.
The timing of a kidney biopsy is disputable and often
depends on the subjective judgment of the clinician.
Empirical treatment with steroids after ruling out pre-
renal and postrenal causes of renal injury is recom-
mended for most patients. A renal biopsy is indicated
directly for patients who are likely to have an alternative
cause of renal injuries, such as glomerulonephritis (i.e.,
not ICI-related), and for patients who do not recover
even with high doses of steroids.Management
In grade 1 AKI, it is recommended to continue ICI and
monitor closely; whereas in grade 2 to 4 AKI, discon-
tinuation of treatment should be done with prompt
initiation of steroids, while at the same time exploring
the exact cause of AKI.54 In patients with grade 4 AKI,
immunotherapy should not be restarted. This review of
observational studies revealed that most patients (80%)
received corticosteroids and that immunotherapy was
discontinued (90%) if ATIN was noted during treatment
with ICI; however, the approach with regard to dose and
length of corticosteroid treatment was highly variable.40
Only one-third of these patients had complete recovery
of their kidney function and 10% of the patients needed
renal replacement therapy. There is a need for better
immunopathophysiologic knowledge and biomarkers to
develop more personalized therapeutic drug regimens
for severe and refractory irAEs.55
In the case of severe kidney injury most likely caused
by chemotherapy, dose reductions or discontinuation
Table 2. Urinalysis in ATIN and ATN
ATIN ATN
WBC þa 0
WBC casts þ 0
RBC þ 0
Protein þ ±
Renal tubular cell casts ± þ
Granular casts 0 þ
aEosinophiluria may be present.
ATIN, acute tubulointerstitial nephritis; ATN, acute tubular necrosis; RBC, red blood cell; WBC, white blood cell.
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ing such recommendations are lacking.56,57 According
to Kintzel et al.,56 in patients treated with cisplatin, a
dose reduction of 25% is suggested for CrCl of 46 to
60 mL/min and a 50% dose reduction for CrCl of 30
to 45 mL/min, whereas Aronoff et al.57 still recom-
mend cisplatin administration in patients with more
severe renal impairment. Substituting cisplatin with
carboplatin is a pragmatic approach in most patients
with advanced NSCLC. For carboplatin, renal function-
based dose adjustments, using the Calvert formula,
are recommended, capping the maximum carboplatin
dose on the basis of the target area under the curve. In
patients treated with pemetrexed, dose adjustment isFigure 3. Kidney biopsy with tubulointerstitial nephritis. (A) H
infiltration in the kidney parenchyma, affecting, and displacing
Immunohistochemical stain for CD3, revealing aggregates of T
cytes, and helper T cells in the interstitial stroma but not pre
stroma and present in intratubular lymphocytes. (E) PD-L1, l
antigen-presenting cells. (F) PD-1 stain, positive in lymphocy
grammed cell death protein-1; PD-L1, programmed death-ligannot necessary for patients with a CrCl greater than
or equal to 45 mL/min, and it is not recommended
to use the drug in patients with a CrCl less than
45 mL/min, although data about these patients are
scarce.58 Pemetrexed dosing is basal surface area–
based; however, increasing evidence suggests that
renal function is the main predictor of pemetrexed
clearance and, thus, exposure.59 Therefore, a renal-
based dosing may result in more stable exposure and
less toxicity. Currently, a phase II study is assessing the
feasibility of renal function–based dosing of peme-
trexed in patients with impaired renal function and
CrCl of less than 45 mL/min (IMPROVE-I, ClinicalTrials.
gov Identifier: NCT03656549).ematoxylin and eosin stain, revealing extensive immune cell
tubules but not encroaching on glomeruli (bottom right). (B)
lymphocytes, and tubulitis. (C) CD4 stain, positive in histo-
sent in tubules. (D) CD8, positive in cytotoxic T cells in the
imited to lymphoid aggregates, likely positive in dendritic/
tes, within and outside of aggregates/follicles. PD-1, pro-
d 1.
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Combination chemotherapy and immunotherapy
with PD-1/PD-L1 inhibition improves survival in pa-
tients with NSCLC. The hypothesis is that chemotherapy
increases the responsiveness to ICI, causing some syn-
ergistic effects, with outcomes superior to the adminis-
tration of both therapies in a sequential way. This also
holds true for the maintenance phase, in which it is
recommended to continue treatment with pemetrexed in
combination with pembrolizumab.
The gain in survival benefit owing to the combination of
chemotherapy and immunotherapy probably increases the
willingness of patients to undergo the treatment. This will
lead to a larger treatment population in clinical practice,
including patients who are frail and are more prone to
treatment adverse effects. Given the advanced age and the
cardiovascular comorbidities often seen in patients with
lung cancer, renal side effects are more frequently seen in a
general population than reported in clinical trials.7
Some important challenges are encountered in clin-
ical practice when dealing with a renal injury during the
combination with chemotherapy and ICI treatment. We
need to be aware of not only the underestimation of
kidney injuries in clinical trials but also of the large
variations in incidence that may be reported owing to
the use of different definitions. In particular, the latest
CTCAE (version 5.0) may falsely report low numbers, as
only kidney disease leading to hospitalization will be
scored. In addition, rather than using a single eGFR and
creatinine measurements alone, we emphasize looking at
the trend during the total treatment period. Further
complications during maintenance treatment may be
predicted not only by the absolute value of the kidney
function but also by its decreasing trend during treat-
ment. For this reason, defining (sub)acute renal injury
according to the AKD definition seems most appropriate.
Proper diagnosis of the causes of adverse effects in
these patients is of utmost importance to preclude the
worsening of adverse effects and decrease in the quality
of life. The algorithm described in this article may help
clinicians diagnose acute kidney injury in patients
treated with a combination of chemotherapy and ICI.Acknowledgments
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